Imunon, Inc. Files Amendment No. 2 to Form S-1 Registration Statement
Ticker: IMNN · Form: S-1/A · Filed: Feb 9, 2024 · CIK: 749647
| Field | Detail |
|---|---|
| Company | Imunon, INC. (IMNN) |
| Form Type | S-1/A |
| Filed Date | Feb 9, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.01, $0.57, $0, $0.0001, $100,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: Imunon, IMNN, S-1/A, SEC Filing, Registration Statement
TL;DR
<b>Imunon, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to register securities.</b>
AI Summary
Imunon, Inc. (IMNN) filed a Amended IPO Registration (S-1/A) with the SEC on February 9, 2024. Imunon, Inc. filed an amendment (No. 2) to its Form S-1 Registration Statement on February 9, 2024. The filing pertains to the Securities Act of 1933. The company's principal executive offices are located at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648. Imunon, Inc. was formerly known as Celsion Corp and Cheung Laboratories Inc. The company is incorporated in Delaware and operates under SIC code 2834 (Pharmaceutical Preparations).
Why It Matters
For investors and stakeholders tracking Imunon, Inc., this filing contains several important signals. This S-1/A filing is a procedural step for Imunon, Inc. to register securities, which is a prerequisite for public offerings or significant capital raises. The amendment suggests the company is actively working through the registration process, potentially signaling upcoming corporate actions or financial activities.
Risk Assessment
Risk Level: low — Imunon, Inc. shows low risk based on this filing. The filing is a routine S-1/A amendment, which does not contain new financial performance data or significant operational updates, thus posing a low immediate risk.
Analyst Insight
Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds.
Key Numbers
- 333-276174 — Registration Number (Form S-1 Registration Statement)
- 20240209 — Filing Date (Amendment No. 2 to Form S-1)
- 08648 — ZIP Code (Principal executive offices address)
- 521256615 — IRS Number (Imunon, Inc.)
- 2834 — SIC Code (Pharmaceutical Preparations)
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Corinne Le Goff (person) — President and Chief Executive Officer
- Megan Gates (person) — Esq. at Covington & Burling LLP
- Michael Riella (person) — Esq. at Covington & Burling LLP
- Ron Ben-Bassat (person) — Esq. at Sullivan & Worcester LLP
- Eric Victorson (person) — Esq. at Sullivan & Worcester LLP
- Celsion Corp (company) — Former company name
- Cheung Laboratories Inc (company) — Former company name
Forward-Looking Statements
- Imunon, Inc. will initiate a public offering of securities. (Imunon, Inc.) — high confidence, target: As soon as practicable after the effective date of this registration statement.
- The offering will be conducted on a delayed or continuous basis. (Imunon, Inc.) — high confidence, target: Ongoing
FAQ
When did Imunon, Inc. file this S-1/A?
Imunon, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on February 9, 2024.
What is a S-1/A filing?
A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Imunon, Inc. (IMNN).
Where can I read the original S-1/A filing from Imunon, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Imunon, Inc..
What are the key takeaways from Imunon, Inc.'s S-1/A?
Imunon, Inc. filed this S-1/A on February 9, 2024. Key takeaways: Imunon, Inc. filed an amendment (No. 2) to its Form S-1 Registration Statement on February 9, 2024.. The filing pertains to the Securities Act of 1933.. The company's principal executive offices are located at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648..
Is Imunon, Inc. a risky investment based on this filing?
Based on this S-1/A, Imunon, Inc. presents a relatively low-risk profile. The filing is a routine S-1/A amendment, which does not contain new financial performance data or significant operational updates, thus posing a low immediate risk.
What should investors do after reading Imunon, Inc.'s S-1/A?
Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds. The overall sentiment from this filing is neutral.
How does Imunon, Inc. compare to its industry peers?
Imunon, Inc. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of pharmaceutical products.
Are there regulatory concerns for Imunon, Inc.?
The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.
Industry Context
Imunon, Inc. operates within the pharmaceutical preparations industry, focusing on the development and commercialization of pharmaceutical products.
Regulatory Implications
The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.
What Investors Should Do
- Review the full S-1/A filing for details on the proposed securities offering.
- Track subsequent SEC filings for updates on the registration statement's effectiveness and any related offering announcements.
- Research Imunon, Inc.'s business operations and financial health to assess the potential investment opportunity.
Key Dates
- 2024-02-09: Filing of Amendment No. 2 to Form S-1 — Indicates ongoing registration process for securities.
Year-Over-Year Comparison
This is an amendment to a previous filing, indicating updates or corrections to the initial registration statement.
Filing Stats: 4,490 words · 18 min read · ~15 pages · Grade level 17.4 · Accepted 2024-02-09 16:09:15
Key Financial Figures
- $0.01 — 7 shares of our common stock, par value $0.01 (“ Common Stock ”), togethe
- $0.57 — sumed combined public offering price of $0.57 (which was the closing price of our Com
- $0 — an assumed exercise price per share of $0.57, equal to the assumed combined publi
- $0.0001 — rice of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will
- $100,000 — lated legal expenses in an amount up to $100,000 and $25,000 for non-accountable expense
- $25,000 — xpenses in an amount up to $100,000 and $25,000 for non-accountable expenses. See &ldqu
Filing Documents
- forms-1a.htm (S-1/A) — 851KB
- ex4-8.htm (EX-4.8) — 110KB
- ex4-9.htm (EX-4.9) — 106KB
- ex5-1.htm (EX-5.1) — 15KB
- ex10-25.htm (EX-10.25) — 332KB
- ex23-1.htm (EX-23.1) — 3KB
- ex107.htm (EX-FILING FEES) — 42KB
- logo_001.jpg (GRAPHIC) — 14KB
- ex5-1_001.jpg (GRAPHIC) — 33KB
- ex5-1_003.jpg (GRAPHIC) — 2KB
- 0001493152-24-005668.txt ( ) — 1527KB
DILUTION
DILUTION 10 USE OF PROCEEDS 11 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 12 EXECUTIVE AND DIRECTOR COMPENSATION 15 EQUITY COMPENSATION PLAN INFORMATION 29 BENEFICIAL OWNERSHIP OF COMMON STOCK 30 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 31 DESCRIPTION OF CAPITAL STOCK 32 DESCRIPTION OF SECURITIES TO BE REGISTERED 37 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 40 DIVIDEND POLICY 47 PLAN OF DISTRIBUTION 48 LEGAL MATTERS 51 EXPERTS 51 WHERE YOU CAN FIND MORE INFORMATION 51 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 52 i CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Certain of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”). Forward-looking statements may relate to such matters as anticipated financial performance, business prospects, technological developments, product pipelines, clinical trials and research and development activities, the adequacy of capital reserves and anticipated operating results and cash expenditures, current and potential collaborations, strategic alternatives and other aspects of our present and future business operations and similar matters. These statements involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Such statements include, without limitation: any
Business
Business Overview Imunon is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across four modalities. The first modality, TheraPlas ® , is being developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine ® , is being developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases. The third modality, FixPlas ® , concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas ® , is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing